QUADRIGA BIOSCIENCES, INC
Los Altos, CA · Biotech · Private
QBS-72S, a nitrogen mustard compound that crosses the blood-brain barrier to treat glioblastoma by inducing DNA inter-strand crosslinks resistant to standard repair mechanisms
- Grants
- $12M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 19
- 10 granted · 9 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Novel targeted Chemotherapeutics for Gliobastoma | $1,018,590 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel targeted Chemotherapeutics for Gliobastoma | $968,230 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters | $1,368,236 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · QBS10072S for the Treatment of Brain Metastatic Triple-Negative Breast Cancer | $1,053,136 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · QBS10072S for the Treatment of Brain Metastatic Triple-Negative Breast Cancer | $1,339,606 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters | $2,692,316 | |
| Federal grant | Department of Health and Human Services · Phase II · QBS10072S for the Treatment of Brain Metastatic Triple-Negative Breast Cancer | $286,470 | |
| Federal grant | Department of Health and Human Services · Phase II · Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters | $1,324,080 | |
| Federal grant | Department of Health and Human Services · Phase II · QBS10072S for the Treatment of Brain Metastatic Triple-Negative Breast Cancer | $702,470 | |
| Federal grant | Department of Health and Human Services · Phase II · Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters | $1,307,447 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2902 | 712 North Inc. | — | — |
| 2903 | SIMMBION LLC | — | — |
| 2904 | Dyno Therapeutics | — | — |
| 2905 | QUADRIGA BIOSCIENCES, INC | — | — |
| 2906 | Tubulis | — | — |
| 2907 | Lyric Therapeutics | — | — |
| 2908 | Beacon Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Pharmaceutical Compositions Of Chemotherapeutic Agents Based On Beta-substituted Beta-amino Acid Derivativesapplication
- Pharmaceutical Compositions Of Chemotherapeutic Agents Based On Beta-substituted Beta-amino Acid Derivativesapplication
- Beta-substituted Beta-amino Acids And Analogs As Chemotherapeutic Agents And Uses Thereofapplication
- Beta-substituted Beta-amino Acids And Analogs As Chemotherapeutic Agents And Uses Thereofgranted
- Beta-substituted Beta-amino Acids And Analogs As Chemotherapeutic Agentsgranted
- Beta-substituted Beta-amino Acids And Analogs As Chemotherapeutic Agentsgranted
- Beta-substituted Beta-amino Acids And Analogs As Chemotherapeutic Agents And Uses Thereofgranted
- Beta-substituted Gamma-amino Acids And Analogs As Chemotherapeutic Agentsgranted
- Beta-substituted Beta-amino Acids And Analogs As Chemotherapeutic Agentsgranted
- Beta-substituted Beta-amino Acids And Analogs As Chemotherapeutic Agents And Uses Thereofgranted
- Beta-substituted Gamma-amino Acids And Analogs As Chemotherapeutic Agentsgranted
- Methods Of Chemotherapy Using Chemotherapeutic Agents Based On Beta-substituted Beta-amino Acids And Analogsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.